References
Feldman H, Gauthier S, Hecker J, et al.: Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 2004, 63:644–650.
Feldman H, Gauthier S, Hecker J, et al.: Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005, 20:559–569.
Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001, 57:613–620.
Tariot PN, Cummings JL, Katz IR, et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001, 49:1590–1599.
Reisberg B, Doody R, Stoffier A, et al.: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003, 348:1333–1341.
Rights and permissions
About this article
Cite this article
Marder, K. Donepezil in patients with severe alzheimer’s disease. Curr Neurol Neurosci Rep 6, 363–364 (2006). https://doi.org/10.1007/s11910-996-0015-x
Issue Date:
DOI: https://doi.org/10.1007/s11910-996-0015-x